Ulcerative Colitis
Conditions
Brief summary
The purpose of the study is to evaluate the PK, safety and tolerability of cobitolimod ememas (500mg/50mL) given to participants with active left-sided UC.
Detailed description
This is a single centre phase 1b study in participants with moderate to severe active UC designed to provide important supplementary data of the PK profile of cobitolimod.
Interventions
DRUGCobitolimod 500mg
Rectal administration
Sponsors
InDex Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Willing and able to give written informed consent for participation in the study. 2. Male or female participant aged ≥18 years. 3. Established diagnosis of UC, with minimum time from diagnosis of at least 3 months before screening. 4. Moderate to severe active left-sided UC (disease should extend 15 cm or more above the anal verge and may extend beyond the splenic flexure) determined by a 3-component Mayo score of 5 to 9 with an endoscopic subscore ≥2 (in sigmoid or descending segments) assessed by the Investigator's reading of the endoscopy, and with a stool frequency and rectal bleeding subscores each ≥1. 5. Clinically acceptable medical history, physical findings, vital signs, ECG and laboratory values at the time of screening, as judged by the Investigator. 6. Women only: WOCBP must practice abstinence (only allowed when this is the preferred and usual lifestyle of the participant) or must agree to use a highly effective method of contraception with a failure rate of \< 1% to prevent pregnancy (combined \[oestrogen and progestogen containing\] hormonal contraception associated with inhibition of ovulation \[oral, intravaginal, transdermal\], progestogen-only hormonal contraception associated with inhibition of ovulation \[oral, injectable, implantable\], intrauterine device \[IUD\] or intrauterine hormone-releasing system \[IUS\]) from at least 4 weeks prior to dose to 4 weeks after last dose. Women of non-childbearing potential are defined as pre-menopausal females who are sterilised (tubal ligation or permanent bilateral occlusion of fallopian tubes); or females who have undergone hysterectomy or bilateral oophorectomy; or post-menopausal defined as 12 months of amenorrhea (in questionable cases a blood sample with detection of follicle stimulating hormone \[FSH\] 25-140 IE/L is confirmatory)
Exclusion criteria
* 1\. Suspicion of differential diagnosis such as Crohn's enterocolitis, ischaemic colitis, radiation colitis, indeterminate colitis, infectious colitis, diverticular disease, associated colitis, microscopic colitis, massive pseudopolyposis or non-passable stenosis. 2\. Acute fulminant UC, toxic megacolon and/or signs of systemic toxicity. 3. Have failed treatment with more than three advanced therapies (infliximab, adalimumab, golimumab, vedolizumab, ustekinumab or tofacitinib) of two different therapeutic classes (anti-TNF, anti-integrins, anti-IL12/23, JAK-inhibitors, or other approved advanced therapies for UC). 4\. Have had surgery for treatment of UC. 5. History of malignancy, unless treated with no relapse of the disease and ≥ 5 years since last treatment (cured) or treated (cured) basal cell or squamous cell in situ carcinoma. 6\. Serious known active infection e.g., any positive result on screening for serum hepatitis B surface antigen, hepatitis C virus antibodies and HIV. 7\. Gastrointestinal infections including positive Clostridium difficile stool assay (local laboratory reports must be available in accordance with normal clinic practice, to confirm that the current episode of disease exacerbation is not due to infection). 8\. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study. 9\. Concomitant or planned treatment with cyclosporine, methotrexate, tacrolimus, or advanced therapies such as infliximab, adalimumab, golimumab, vedolizumab, ustekinumab or tofacitinib, or similar immunosuppressants and immunomodulators at enrolment. Any prior treatment with such drugs must have been discontinued at least 8 weeks prior to Visit 1 (except for ustekinumab, which must have been discontinued at least 12 weeks prior to Visit 1) or have non-measurable serum concentration levels. 10\. Treatment with rectal GCS, 5-ASA/SP or tacrolimus within 2 weeks before Visit 1. 11\. Long-term treatment (\>14 days) with antibiotics or non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to Visit 1 (one short treatment regimen for antibiotics, occasional use of NSAIDs and low dose NSAIDs as prophylactic therapy is allowed). 12\. Females who are lactating or have a positive serum pregnancy test at Visit 1. 13\. Any planned major surgery within the duration of the study. 14. Planned treatment or treatment with another investigational drug within 3 months prior to Day -1. 15\. Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the three months prior to screening. 16\. Investigator considers the participant unlikely to comply with study procedures, restrictions and requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Half-life (T1/2) | week 6 | Half-life (T1/2) |
| Time to Cmax (Tmax) | Week 6 | Time to Cmax (Tmax) |
| Area under the curve from 0 to timepoint t (AUCt) | week 6 | Area under the curve from 0 to timepoint t (AUCt) |
| AUC from 0 to infinity (AUCinf) | week 6 | AUC from 0 to infinity (AUCinf) |
| Maximum observed plasma concentrations (Cmax) | Week 6 | Maximum observed plasma concentrations (Cmax) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinically significant changes in electrocardiogram (ECG), vital signs, safety laboratory | week 8 | Abnormal post-dose findings assessed by the Investigator as clinically significant will be reported as AEs. |
| Significant changes in blood biomarkers | week 8 | The difference between biomarker expression before and after treatment will be reported. |
| Frequency, intensity and seriousness of adverse events (AEs) | week 8 | Frequency, intensity and seriousness of adverse events (AEs) |
Countries
Sweden
Contacts
Primary ContactJohan Levin, PM
Backup ContactKarin Arnesson, CTM
Outcome results
None listed